



Healthcare Expenditure Burden Among Non-elderly Cancer Survivors, 2008-2012

Gery P. Guy Jr. , *Centers for Disease Control and Prevention*
K. Robin Yabroff, *National Cancer Institute*
Donatus U. Ekwueme, *Centers for Disease Control and Prevention*
[Katherine S Virgo](#), *Emory University*
[Xuesong Han](#), *Emory University*
Matthew P. Banegas, *Kaiser Permanente Northwest*
Anita Soni, *Center for Financing, Access, and Cost Trend*
Zhiyuan Zheng, *American Cancer Society*
Neetu Chawla, *Kaiser Permanente Northern California*
Ann M. Geiger, *National Cancer Institute*

Journal Title: American Journal of Preventive Medicine
Volume: Volume 49, Number 6
Publisher: Elsevier: 12 months | 2015-12-01, Pages S489-S497
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.amepre.2015.09.002
Permanent URL: <https://pid.emory.edu/ark:/25593/t5n6z>

Final published version: <http://dx.doi.org/10.1016/j.amepre.2015.09.002>

Copyright information:

© 2018 Elsevier Inc. All rights reserved.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Accessed November 18, 2019 2:09 PM EST



Published in final edited form as:

Am J Prev Med. 2015 December ; 49(6 Suppl 5): S489–S497. doi:10.1016/j.amepre.2015.09.002.

Healthcare Expenditure Burden Among Non-elderly Cancer Survivors, 2008–2012

Gery P. Guy Jr., PhD, MPH¹, K. Robin Yabroff, PhD, MBA², Donatus U. Ekwueme, PhD, MS¹, Katherine S. Virgo, PhD, MBA³, Xuesong Han, PhD⁴, Matthew P. Banegas, PhD, MPH⁵, Anita Soni, PhD⁶, Zhiyuan Zheng, PhD⁴, Neetu Chawla, PhD, MPH⁷, and Ann M. Geiger, PhD, MPH²

¹Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, CDC, Atlanta, Georgia ²Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland ³Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, Georgia ⁴Surveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia ⁵Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon ⁶Agency for Healthcare Research and Quality, Center for Financing, Access, and Cost Trends, Rockville, Maryland ⁷Division of Research, Kaiser Permanente Northern California, Oakland, California

Abstract

Introduction: There is increasing concern regarding the financial burden of cancer on patients and their families. This study presents nationally representative estimates of annual out-of-pocket (OOP) burden among non-elderly cancer survivors and assesses the association between high OOP burden and access to care and preventive service utilization.

Methods: Using the 2008–2012 Medical Expenditure Panel Survey, 4,271 cancer survivors and 96,780 individuals without a history of cancer were identified, all aged 18–64 years. High annual OOP burden was defined as spending > 20% of annual family income on OOP healthcare costs. Associations between high OOP burden and access to care were evaluated with multivariable logistic regression. Analyses were conducted in 2015.

Results: Compared with individuals without a cancer history, cancer survivors were more likely to report a high OOP burden (4.3% vs 3.4%, $p=0.009$) in adjusted analyses. High OOP burden was more common among cancer survivors who were poor (18.4%), with either public insurance (7.9%) or uninsured (5.7%), and not working (10.2%). Among cancer survivors, high OOP burden was associated with being unable to obtain necessary medical care (19.2% vs 12.5%, $p=0.002$), delaying necessary medical care (21.6% vs 13.8%, $p=0.002$), and lower breast cancer screening rates among age-appropriate women (63.2% vs 75.9%, $p=0.02$).

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Address correspondence to: Gery P. Guy, Jr., PhD, MPH, Division of Cancer Prevention and Control, CDC, 4770 Buford Highway, NE, MS K-76, Atlanta GA 30341. irm2@cdc.gov.

No financial disclosures were reported by the authors of this paper.

Conclusions: High OOP burden is more common among adults with a cancer history than those without a cancer history. High OOP burden was associated with being unable to obtain necessary medical care, delaying necessary medical care, and lower breast cancer screening rates among women.

Introduction

An estimated 14.5 million Americans with a history of cancer were alive in 2014.¹ Previous research has shown that cancer survivors face greater healthcare expenditures including out-of-pocket (OOP) costs compared with individuals without a history of cancer.^{2–5} High OOP costs can reduce access to care, influence clinical practice, and affect treatment choices.^{6,7} By creating a financial barrier, OOP payments can lead to reduced use of preventive services and uptake of preventive medications.^{6,8} For example, higher OOP costs are associated with lower rates of screening for breast cancer, cervical cancer, and colorectal cancer among certain populations.^{8–10} Reduced access to care among cancer survivors may affect surveillance and treatment for disease recurrence, screening for additional cancers, and care for the late and lasting effects of cancer treatment.^{11,12}

Limited information exists on OOP burden among cancer survivors at the national level. Previous studies have addressed OOP burden among cancer survivors by treatment status, rather than among all cancer survivors together,^{5,13} or have focused on cancer patients aged 65 years.¹³ Additionally, few studies have evaluated the association between OOP burden and access to care and preventive service utilization among cancer survivors. This study provides a comprehensive analysis of OOP burden among non-elderly adult cancer survivors aged 18–64 years. Using nationally representative data, this study examines the prevalence of high annual OOP burden and the association between high annual OOP burden and access to care and preventive service utilization among non-elderly cancer survivors.

Methods

Data Sources

The study sample was selected from the 2008–2012 Medical Expenditure Panel Survey (MEPS) Household Component. The MEPS is a nationally representative sample of the U.S. civilian non-institutionalized population that collects detailed information on demographic characteristics, health status, income, health insurance, employment, access to care, and healthcare expenditures (including OOP expenditures). In-person interviews are conducted with an individual who responds for all members of the household. The annual response rate ranged from 53.5% to 59.3% during the study years included in the analysis. More-detailed information on the MEPS survey design and content is available elsewhere.^{14,15}

Cancer survivors were defined as any person who has ever been diagnosed with cancer. Using the 2008–2012 MEPS, 4,271 cancer survivors aged 18–64 years were identified based on the question: *Has a doctor or other health provider ever told you that you have a cancer or malignancy of any kind?* The comparison group consisted of the remaining 96,780 adults in the same age range who did not report a history of cancer. Similar to previous studies,

individuals diagnosed solely with non-melanoma skin cancer were not classified as cancer survivors.^{2,16}

Measures

Sociodemographic characteristics of cancer survivors at the time of the survey included: time since diagnosis, age, sex, race/ethnicity, educational attainment, marital status, number of comorbid conditions, health status, health insurance status, employment status, and family income as a percentage of the federal poverty level (FPL). Poor people were defined as having family income < 100% FPL, near-poor and low-income people were defined as having income 100%–200% FPL, and middle- and high-income people were defined as having incomes ≥ 200% of FPL. The number of comorbid conditions was determined through a series of questions about whether a doctor or other healthcare professional ever told the person that they had any MEPS priority condition, including arthritis, asthma, diabetes, emphysema, heart disease, hypertension, stroke, and high cholesterol.

Annual OOP burden was measured as the percentage of OOP costs relative to family income. Annual OOP burden included OOP expenditures toward any healthcare service, such as coinsurance, copayments, and deductibles. Expenditures include those for cancer screening, surveillance, and treatment, as well as medical care for other health conditions. Consistent with previous research, OOP burden was defined at the family level, as families typically share financial resources.⁵ Family-level burdens were assigned to individuals within the family, allowing the analysis to be conducted at the individual level. Similar to previous studies, high OOP burden was defined as having annual OOP spending > 20% of annual income.^{5,17} For families reporting very low or negative incomes (1.8% of cancer survivors in the sample), a \$100 floor for family income was imposed.⁵ The results were not sensitive to the adjustment.

Several access to care measures were evaluated based on both the availability of care and actual utilization of healthcare services in the past year. Access to care measures included:

- having a usual source of care;
- having difficulty getting to a usual source of care;
- being unable to get necessary medical care, dental care, or prescription medications; and
- delaying necessary medical care, dental care, or use of prescription medications.

Preventive care was evaluated by examining preventive service use and cancer screening services recommended by the U.S. Preventive Services Task Force¹⁸ and vaccinations recommended by the Advisory Committee on Immunization Practices¹⁹ and potentially covered by provisions of the Affordable Care Act (ACA). Preventive services included:

- blood pressure screening within the past 2 years;
- cholesterol screening within the past 2 years;
- influenza vaccination in the past year; and

- breast, cervical, and colorectal cancer screening within recommended screening guidelines.

Cancer screening was assessed among age- and gender-eligible men and women. Receipt of mammography within the past 2 years among women aged ≥ 40 years was used to identify women up to date with breast cancer screening guidelines. Receipt of the Pap test within the past 3 years among women aged 21–64 years who had not had their cervix removed was used to identify women up to date with cervical cancer screening guidelines. Adherence to colorectal cancer screening guidelines was assessed by examining the receipt of a fecal occult blood test within 1 year, sigmoidoscopy within the last 5 years, or colonoscopy within the last 10 years among men and women aged 50–64 years to identify individuals up to date with screening. Individuals with a history of the specific cancer in each analysis were excluded to ensure that preventive screenings were captured rather than surveillance.²⁰

Statistical Analysis

Descriptive statistics were calculated for cancer survivors and individuals without a history of cancer and compared using chi-square statistics. Multivariable logistic regression models controlling for age, sex, race/ethnicity, marital status, education, and number of comorbidities were used to compare annual OOP burden among cancer survivors and individuals without a history of cancer. Overall results and results stratified by demographic factors as well as family income, health insurance, and employment status are presented. The adjusted percentages of adults with a high OOP burden are presented as predictive margins, which standardize the outcome of each group to the covariate distribution of the population.²¹

Multivariable logistic regression models were used to assess the relationship between high OOP burden and access to care and preventive service utilization among cancer survivors. Predictive margins were generated to compare these measures among cancer survivors by OOP burden status controlling for age, sex, race/ethnicity, marital status, education, and number of comorbidities.

Person-level weights were applied to account for the complex study design of the MEPS and reflected probability of selection, adjustments for non-response, and post-stratification to provide nationally representative estimates. All analyses were conducted using Stata, version 14.0. Analyses were conducted in 2015.

Results

Cancer survivors were more likely to be older, female, non-Hispanic white, have more comorbid conditions, report being in fair or poor health, insured, more likely to be married, and more likely not to be working than individuals without a history of cancer (Table 1). More than a third of cancer survivors (36.7%) were diagnosed within the past 4 years, and 39.1% were diagnosed at least 10 years before the survey.

Cancer survivors were more likely to have a high annual OOP burden compared with those without a history of cancer. After adjusting for other covariates, 4.3% of cancer survivors had a high OOP burden compared with 3.4% of individuals without a history of cancer

($p=0.009$, Table 2). Among individuals aged 50–64 years, cancer survivors were more likely to report a high total OOP burden than individuals without a history of cancer ($p=0.02$), whereas similar rates of high OOP burden were found among those aged 18–49 years regardless of their cancer history. Near-poor and low-income along with middle- and high-income cancer survivors were more likely to have a high annual OOP burden compared with individuals in the same poverty level categories but without a history of cancer ($p=0.02$ and $p=0.003$, respectively). High OOP burden was more common among privately insured cancer survivors than among privately insured individuals without a history of cancer ($p < 0.001$). High OOP burden was more common among cancer survivors working full-time than among individuals without a history of cancer working full-time ($p=0.02$).

Among cancer survivors, the prevalence of high annual OOP burden varied across a number of sociodemographic characteristics. High OOP burden was more common among the poor (18.4%) and the near-poor and low-income (4.6%), compared with those with middle and high incomes (1.0%). Among cancer survivors, high OOP burden was more common among those with public insurance (7.9%) and the uninsured (5.7%) compared with cancer survivors with private health insurance (3.2%). High OOP burden was more common among cancer survivors who were not working (10.2%) compared with those working part-time (4.2%) and those working full-time (1.7%).

Cancer survivors with a high annual OOP burden were more likely to report that they were unable to obtain necessary medical care, dental care, or prescription medications (19.2% vs 12.5%, $p=0.002$) and delayed necessary care (21.6% vs 13.8%, $p=0.002$) compared with cancer survivors without a high OOP burden (Table 3). Among female cancer survivors, breast cancer screening rates were lower among those with a high OOP burden compared with those without a high OOP burden (63.2% vs 75.9%, $p=0.02$).

Discussion

This study demonstrates that cancer survivors are more likely to report a high annual OOP burden than individuals without a history of cancer. High annual OOP burden is more common among poor cancer survivors, those with public insurance or the uninsured, and those not working. Among cancer survivors, high OOP burden is associated with being unable to obtain necessary medical care and delaying necessary medical care. Additionally, high OOP burden is associated with lower breast cancer screening among age-appropriate female cancer survivors.

Although there is literature underscoring the financial burden of cancer survivorship, this is the first study to quantify the prevalence of high annual OOP burden and its association with access to health care and preventive service utilization among non-elderly cancer survivors at the national level. These findings support previous research among cancer survivors highlighting the association between higher cost sharing requirements and forgoing or delaying medical care.^{22,23} Access to care is particularly important for cancer survivors, given their increased risk of developing other chronic conditions, and long-term adverse health effects, including cardiotoxicity, lymphedema, sexual dysfunction, incontinence, pain, fatigue, cognitive dysfunction, and psychological distress.^{24,25} Cancer survivors also have an

increased risk of secondary cancers.^{26,27} Previous studies have highlighted disparities in access to care among cancer survivors and the importance of ongoing efforts to improve access to care among this population.²⁰

The findings suggest that non-elderly female cancer survivors who reported a high annual OOP burden were less likely to report having a recent mammogram. Access to recommended preventive care such as breast cancer screening is critical for cancer survivors, as they are at an increased risk of developing other cancers and may experience late and lasting effects of cancer treatment.^{25–27} The ACA provides many opportunities for prevention. Millions of Americans are now eligible for health insurance coverage through the Health Insurance Marketplace and Medicaid expansion in most states, giving them better access to health services, including preventive services. The ACA requires non-grandfathered private health plans and newly eligible beneficiaries of the Medicaid expansion to provide coverage without cost sharing for preventive services rated as “A” (strongly recommended) or “B” (recommended) by the U.S. Preventive Services Task Force, for vaccinations recommended by the Advisory Committee on Immunization Practices, and services for infants, women, and children recognized by the Health Resources and Services Administration.²⁸ By requiring many plans to cover recommended clinical preventive services with no cost sharing to the patient, including screening for breast, cervical, and colorectal cancer, the ACA can help reduce financial barriers to the receipt of recommended preventive care. However, it is not clear if these changes alone will increase access to care among cancer survivors faced with high annual OOP burden. Other barriers such as lack of paid sick leave may inhibit the receipt of recommended preventive services.²⁹ Ongoing evaluation of access to recommended preventive care will be important as the ACA continues to be implemented.³⁰

The current study found that high annual OOP burden is associated with higher rates of delaying or forgoing needed medical care among cancer survivors. Delaying or forgoing needed medical care among cancer survivors may negatively affect surveillance for disease recurrence and care for the late and lasting effects of cancer treatment.^{11,12} Higher OOP costs have also been shown to reduce adherence to cancer treatment.^{23,31} In a survey of medical oncologists, 84% reported that patient OOP spending influenced treatment recommendations,⁷ with 16% acknowledging that they omitted treatment options on the basis of their perceptions of patients’ ability to afford treatment.³² The American Society of Clinical Oncology Value in Cancer Care Task Force has emphasized the important role of patient and provider communication on issues surrounding cost.³³ However, many physicians may be uncomfortable discussing costs with patients.³² The negative impact on the health of cancer patients because of high OOP costs and the financial burden associated with treatment related to cancer has been characterized by Ubel and colleagues³⁴ as “financial toxicity.” As these authors have explained, providers frequently discuss toxicities of treatment, but these discussions typically refer to the physical side effects of treatment. Meanwhile, financial toxicities can also have a substantial impact on the quality of life of patients and their families. Patients may be faced with choosing between health care related to their cancer or paying for daily living expenses.³⁴ Previous research has shown that cancer patients were more likely to file bankruptcy than individuals without a history of cancer, with the risk of bankruptcy two to five times higher among non-elderly patients

given greater variations in employment, income, insurance status, and personal assets.³⁵ Open dialogue between providers and their patients about these issues could help enable informed decision making that carefully considers both expected benefits and potential high OOP costs of treatments.³⁵

Limitations

Although the MEPS is one of the most detailed nationally representative data sources available to estimate OOP burden among cancer survivors and individuals without a cancer history, there are a number of limitations in this study. First, this study relied on household-reported data, which introduces potential reporting biases. For example, the cancer diagnosis question in the MEPS refers to cancer or a malignancy of any kind, which may result in identifying those with pre-invasive disease as cancer survivors. To the extent that this is the case, the impact of cancer survivorship on OOP burden would be underestimated. Second, this study used family pre-tax income rather than post-tax income to compute OOP burden. Although post-tax income may be a more accurate measure of financial resources available to a family, previous research using the MEPS found that OOP burden prevalence was very similar when using pre-tax income, and variations in sociodemographic characteristics were virtually identical.³⁶ Lastly, the results only apply to the non-institutionalized civilian adult population.

Conclusions

High annual OOP burden is more common among cancer survivors than individuals without a cancer history. High OOP burden has the potential to reduce access to care and the utilization of preventive services. With the continuing increase in the number of cancer survivors and rising healthcare costs, trends in OOP burden among cancer survivors and efforts to improve communication between patients and providers about cost will be important to monitor and follow.

Acknowledgments

Publication of this article was supported by the Centers for Disease Control and Prevention, Division of Cancer Prevention and Control.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC, NIH, the Agency for Healthcare Research and Quality, Emory University, or the American Cancer Society.

References

1. DeSantis CE, Lin CC, Mariotto AB. Cancer treatment and survivorship statistics, 2014 *CA Cancer J Clin.* 2014; 64(4):252–271. . DOI: 10.3322/caac.21235 [PubMed: 24890451]
2. Guy G Jr, Ekwueme D, Yabroff K. The economic burden of cancer survivorship among adults in the United States *J Clin Oncol.* 2013; 31(30):3749–3757. . DOI: 10.1200/JCO.2013.49.1241 [PubMed: 24043731]
3. Yabroff KR, Lamont EB, Mariotto A. Cost of care for elderly cancer patients in the United States *J Natl Cancer Inst.* 2008; 100(9):630–641. . DOI: 10.1093/jnci/djn103 [PubMed: 18445825]

4. Short PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged < 65 years in the United States *Cancer*. 2011; 117(12):2791–2800. . DOI: 10.1002/cncr.25835 [PubMed: 21656757]
5. Bernard DSM, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008 *J Clin Oncol*. 2011; 29(20):2821–2826. . DOI: 10.1200/JCO.2010.33.0522 [PubMed: 21632508]
6. Rezaayatmand R, Pavlova M, Groot W. The impact of out-of-pocket payments on prevention and health-related lifestyle: a systematic literature review *Eur J Public Health*. 2013; 23(1):74–79. . DOI: 10.1093/eurpub/cks034 [PubMed: 22544911]
7. Neumann PJ, Palmer JA, Nadler E, Fang C, Ubel P. Cancer therapy costs influence treatment: a national survey of oncologists *Health Aff (Millwood)*. 2010; 29(1):196–202. . DOI: 10.1377/hlthaff.2009.0077 [PubMed: 20048377]
8. Trivedi AN, Rakowski W, Ayanian JZ. Effect of cost sharing on screening mammography in Medicare health plans *N Engl J Med*. 2008; 358(4):375–383. . DOI: 10.1056/NEJMsa070929 [PubMed: 18216358]
9. Guy GP Jr. The effects of cost sharing on access to care among childless adults *Health Serv Res*. 2010; 45(6 Pt 1):1720–1739. . DOI: 10.1111/j.1475-6773.2010.01162.x [PubMed: 20819108]
10. Khatami S, Xuan L, Roman R. Modestly increased use of colonoscopy when copayments are waived *Clin Gastroenterol Hepatol*. 2012; 10(7):761–766 e1. . DOI: 10.1016/j.cgh.2012.02.027 [PubMed: 22401903]
11. Sabatino SA, Thompson TD, Richardson LC, Miller J. Health insurance and other factors associated with mammography surveillance among breast cancer survivors: results from a national survey *Med Care*. 2012; 50(3):270–276. . DOI: 10.1097/MLR.0b013e318244d294 [PubMed: 22193416]
12. Brewster AM, Hortobagyi GN, Broglio KR. Residual risk of breast cancer recurrence 5 years after adjuvant therapy *J Natl Cancer Inst*. 2008; 100(16):1179–1183. . DOI: 10.1093/jnci/djn233 [PubMed: 18695137]
13. Davidoff AJ, Erten M, Shaffer T. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer *Cancer*. 2013; 119(6):1257–1265. . DOI: 10.1002/cncr.27848 [PubMed: 23225522]
14. Cohen JW, Monheit AC, Beauregard KM. The Medical Expenditure Panel Survey: a national health information resource *Inquiry*. 1996; 33(4):373–389. [PubMed: 9031653]
15. Agency for Healthcare Research and Quality: *MEPS Survey Background*. mepsweb/about_meps/survey_back.jsp. Accessed January 15, 2015.
16. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample *J Natl Cancer Inst*. 2004; 96(17):1322–1330. . DOI: 10.1093/jnci/djh255 [PubMed: 15339970]
17. Banthin JS, Bernard DM. Changes in financial burdens for health care: national estimates for the population younger than 65 years, 1996 to 2003 *JAMA*. 2006; 296(22):2712–2719. . DOI: 10.1001/jama.296.22.2712 [PubMed: 17164457]
18. U.S. Preventive Services Task Force. *USPSTF A and B Recommendations*. www.uspreventiveservicestaskforce.org/Page/Name/uspstf-a-and-b-recommendations/#dag. Accessed January 15, 2015.
19. CDC. *Influenza ACIP Vaccine Recommendations*. www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. Accessed January 15, 2015.
20. Yabroff KR, Short PF, Machlin S. to preventive health care for cancer survivors *Am J Prev Med*. 2013; 45(3):304–312. . DOI: 10.1016/j.amepre.2013.04.021 [PubMed: 23953357]
21. Graubard BI, Korn EL. Predictive margins with survey data *Biometrics*. 2004; 55(2):652–659. . DOI: 10.1111/j.0006-341X.1999.00652.x
22. Kent EE, Forsythe LP, Yabroff KR. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? *Cancer*. 2013; 119(20):3710–3717. . DOI: 10.1002/cncr.28262 [PubMed: 23907958]

23. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia *J Clin Oncol*. 2014; 32(4): 306–311. . DOI: 10.1200/JCO.2013.52.9123 [PubMed: 24366936]
24. Hewitt M, Greenfield S, Stovall E. *From Cancer Patient to Cancer Survivor: Lost in Transition*. Washington, DC : The National Academies Press ; 2005.
25. Hudson MM, Landier W, Ganz PA. Impact of survivorship-based research on defining clinical care guidelines *Cancer Epidemiol Biomarkers Prev*. 2011; 20(10):2085–2092. . DOI: 10.1158/1055-9965.EPI-11-0642 [PubMed: 21980016]
26. Ng AK, Travis LB. Second primary cancers: an overview *Hematol Oncol Clin North Am*. 2008; 22(2):271–289. [PubMed: 18395150]
27. Oeffinger KC, Bhatia S. Second primary cancers in survivors of childhood cancer *Lancet*. 2009; 374(9700):1484–1485. . DOI: 10.1016/S0140-6736(09)61885-7 [PubMed: 19880005]
28. Fox JB, Shaw FE. Clinical preventive services coverage and the Affordable Care Act *Am J Public Health*. 2014; 105(1):e7–e10. . DOI: 10.2105/AJPH.2014.302289
29. Peipins LA, Soman A, Berkowitz Z, White MC. The lack of paid sick leave as a barrier to cancer screening and medical care-seeking: results from the National Health Interview Survey *BMC Public Health*. 2012; 12(1):520. . doi: 10.1186/1471-2458-12-520 [PubMed: 22788387]
30. Davidoff A, Hill S, Bernard D, Yabroff KR. The Affordable Care Act and expanded insurance eligibility among nonelderly adult cancer survivors *J Natl Cancer Inst*. 2015; 107(9) [10.1093/jnci/djv181](https://doi.org/10.1093/jnci/djv181).
31. Neugut AI, Subar M, Wilde ET. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer *J Clin Oncol*. 2011; 29(18):2534–2542. . DOI: 10.1200/JCO.2010.33.3179 [PubMed: 21606426]
32. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey *J Clin Oncol*. 2007; 25(2):233–237. . DOI: 10.1200/JCO.2006.09.2437 [PubMed: 17210946]
33. Meropol NJ, Schrag D, Smith TJ. American Society of Clinical Oncology guidance statement: the cost of cancer care *J Clin Oncol*. 2009; 27(23):3868–3874. . DOI: 10.1200/JCO.2009.23.1183 [PubMed: 19581533]
34. Ubel PA, Abernethy AP, Zafar SY. Full disclosure—out-of-pocket costs as side effects *N Engl J Med*. 2013; 369(16):1484–1486. . DOI: 10.1056/NEJMp1306826 [PubMed: 24131175]
35. Ramsey S, Blough D, Kirchhoff A. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis *Health Aff (Millwood)*. 2013; 32(6):1143–1152. . DOI: 10.1377/hlthaff.2012.1263 [PubMed: 23676531]
36. Cunningham PJ. The growing financial burden of health care: national and state trends, 2001-2006 *Health Aff (Millwood)*. 2010; 29(5):1037–1044. . DOI: 10.1377/hlthaff.2009.0493 [PubMed: 20338908]

Table 1.

Characteristics of Nonelderly Cancer Survivors and Individuals Without a History of Cancer: Medical Expenditure Panel Survey, 2008-2012

| Characteristics | Cancer survivors, % (95% CI) (n=4,271) | Individuals without a history of cancer, % (95% CI) (n=96,780) | p-value |
|--------------------------------------|--|--|---------|
| Time since diagnosis (years) | | | |
| 0–4 | 36.7 (34.3–39.1) | – | |
| 5–9 | 22.4 (20.8–24.2) | – | |
| 10–19 | 23.8 (21.9–25.8) | – | |
| 20 | 15.3 (13.6–17.1) | – | |
| Missing | 1.9 (1.3–2.7) | – | |
| Age (years) | | | <0.001 |
| 18–39 | 15.1 (13.5–16.9) | 48.9 (48.0–49.7) | |
| 40–49 | 20.0 (18.2–21.8) | 21.7 (21.2–22.3) | |
| 50–64 | 64.9 (62.5–67.3) | 29.4 (28.6–30.3) | |
| Sex | | | <0.001 |
| Men | 35.0 (32.7–37.3) | 50.1 (49.7–50.5) | |
| Women | 65.0 (62.7–67.3) | 49.9 (49.5–50.3) | |
| Race/ethnicity | | | <0.001 |
| Non-Hispanic white | 81.3 (79.2–83.1) | 63.9 (62.0–65.8) | |
| Non-Hispanic black | 7.9 (6.7–9.2) | 12.3 (11.1–13.7) | |
| Hispanic | 7.3 (6.2–8.6) | 16.2 (14.6–18.0) | |
| Non-Hispanic other | 3.6 (2.7–4.8) | 7.5 (6.6–8.5) | |
| Education | | | <0.001 |
| Less than high school graduate | 11.7 (10.4–13.2) | 15.5 (14.8–16.2) | |
| High school graduate | 27.7 (25.7–29.9) | 28.4 (27.6–29.3) | |
| Some college or more | 60.4 (58.0–62.9) | 55.7 (54.5–56.8) | |
| Marital status | | | <0.001 |
| Married | 61.5 (58.7–64.3) | 52.2 (51.3–53.1) | |
| Not married | 38.5 (35.7–41.3) | 47.8 (46.9–48.7) | |
| Number of comorbidities ^a | | | <0.001 |
| None | 24.7 (22.5–27.0) | 51.6 (50.9–52.3) | |
| One | 24.8 (22.8–27.0) | 23.9 (23.4–24.3) | |
| Two | 21.1 (19.1–23.2) | 12.9 (12.5–13.3) | |
| Three or more | 29.4 (27.2–31.7) | 11.6 (11.2–12.1) | |
| Health status | | | <0.001 |
| Excellent/Very good | 40.8 (38.5–43.0) | 62.3 (61.4–63.1) | |
| Good | 31.1 (29.3–33.0) | 27.1 (26.4–27.7) | |
| Fair/Poor | 28.1 (26.2–30.0) | 10.7 (10.3–11.1) | |
| Health insurance | | | 0.03 |
| Any private | 74.4 (72.3–76.5) | 70.5 (69.3–71.7) | |
| Public only | 14.9 (13.3–16.6) | 10.6 (10.0–11.3) | |

| Characteristics | Cancer survivors, % (95% CI) (n=4,271) | Individuals without a history of cancer, % (95% CI) (n=96,780) | p-value |
|---|--|--|------------------|
| Uninsured | 10.7 (9.3–12.2) | 18.9 (17.9–19.8) | |
| Employment status | | | <0.001 |
| Full time | 51.3 (48.5–54.1) | 61.4 (60.7–62.1) | |
| Part time | 16.5 (14.8–18.2) | 18.9 (18.4–19.4) | |
| Not working | 32.2 (30.0–34.6) | 19.7 (19.1–20.3) | |
| Family income | | | <0.001 |
| Poor (<100% FPL) | 12.8 (11.6–14.1) | 13.1 (12.4–13.8) | |
| Near poor and low income (100%–200% FPL) | 14.6 (13.2–16.1) | 16.5 (15.9–17.1) | |
| Middle and high income (> 200% FPL) | 72.5 (70.5–74.4) | 70.2 (69.2–71.3) | |
| OOP healthcare expenditures (\$) ^b | 2,171 (1,970–2,373) | 1,409 (1,360–1,459) | <0.001 |

Note: Boldface indicates statistical significance ($p < 0.05$). Sample sizes are unweighted.

^aComorbidities include arthritis, asthma, diabetes, emphysema, heart disease, hypertension, stroke, and high cholesterol.

^bOOP health care expenditures are in 2012 U.S. dollars.

FPL, federal poverty level; OOP, out-of-pocket.

Table 2.

Prevalence of High OOP Burden^a Among Nonelderly Cancer Survivors and Individuals Without a History of Cancer: Medical Expenditure Panel Survey, 2008–2012

| Characteristics | Cancer survivors, % (95% CI) ^b (n=4,271) | Individuals without a history of cancer, % (95% CI) ^b (n=96,780) | p-value |
|---|---|---|------------------|
| Total | 4.3 (3.5–5.0) | 3.4 (3.2–3.6) | 0.009 |
| Age (years) | | | |
| 18–39 | 3.8 (2.3–5.3) | 2.8 (2.6–3.0) | 0.13 |
| 40–49 | 3.4 (2.1–4.6) | 3.2 (2.9–3.6) | 0.81 |
| 50–64 | 5.7 ^c (4.4–6.9) | 4.3 (3.8–4.7) | 0.02 |
| Sex | | | |
| Men | 4.1 (2.9–5.3) | 2.9 (2.8–3.1) | 0.04 |
| Women | 4.6 (3.8–5.5) | 3.8 (3.5–4.0) | 0.04 |
| Race/ethnicity | | | |
| Non-Hispanic white | 4.2 (3.3–5.0) | 3.4 (3.1–3.6) | 0.046 |
| Non-Hispanic black | 5.3 (3.5–7.1) | 4.0 (3.6–4.4) | 0.13 |
| Hispanic | 4.3 (2.6–5.9) | 3.0 (2.7–3.4) | 0.11 |
| Non-Hispanic other | 3.8 (1.1–6.5) | 3.2 (2.6–3.8) | 0.60 |
| Family income | | | |
| Poor (<100% FPL) | 18.4 ^d (15.1–21.7) | 19.3 (18.2–20.3) | 0.63 |
| Near poor and low income (100%–200% FPL) | 4.6 ^d (3.2–6.1) | 3.2 (2.7–3.6) | 0.02 |
| Middle and high income (> 200% FPL) | 1.0 (0.5–1.5) | 0.5 (0.4–0.6) | 0.003 |
| Health insurance | | | |
| Any private | 3.2 (2.4–4.0) | 1.9 (1.7–2.1) | <0.001 |
| Public only | 7.9 (5.9–9.8) | 8.5 (7.8–9.2) | 0.55 |
| Uninsured | 5.7 (4.1–7.3) | 6.1 (5.6–6.6) | 0.63 |
| Employment status | | | |
| Full time | 1.7 (1.1–2.2) | 1.1 (1.0–1.2) | 0.02 |
| Part time | 4.2 (2.5–6.0) | 3.1 (2.8–3.5) | 0.19 |
| Not working | 10.2 ^e (8.4–12.1) | 10.5 (9.8–11.2) | 0.77 |

Note: Boldface indicates statistical significance ($p < 0.05$).

^aHigh OOP burden was defined as having annual out-of-pocket expenditures on healthcare services in excess of 20% of annual family income.

^bPredicted marginals from a logistic regression model controlling for age, sex, race/ethnicity, marital status, education, and number of comorbidities.

^cHigh OOP burden was higher among cancer survivors age 50–64 years than among cancer survivors age 18–39 years ($p < 0.05$).

^dHigh OOP burden was higher among poor and near poor and low-income cancer survivors than among middle and high-income cancer survivors ($p < 0.05$).

^eHigh OOP burden was higher among not working cancer survivors than among cancer survivors working full time and part time ($p < 0.05$).

FPL, federal poverty level; OOP, out-of-pocket.

Table 3.

Access to Care and Preventive Service Utilization Among Nonelderly Cancer Survivors by OOP Burden: Medical Expenditure Panel Survey, 2008–2012

| | High^a | | Not high | | p-value |
|--|-------------------------|-------------------------------|-----------------|-------------------------------|----------------|
| | n | % (95% CI)^b | n | % (95% CI)^b | |
| Access to care | | | | | |
| Has a usual source of care | 272 | 83.3 (77.9–88.6) | 3,999 | 86.7 (85.2–88.1) | 0.18 |
| Difficult to get to usual healthcare provider (somewhat or very difficult) among those with usual source of care | 272 | 9.2 (4.8–13.6) | 3,999 | 6.3 (5.3–7.3) | 0.15 |
| Unable to get necessary medical care, dental care, or prescription medication | 272 | 19.2 (14.5–24.0) | 3,999 | 12.5 (11.2–13.7) | 0.002 |
| Delayed any necessary medical care, dental care, or prescription medication | 272 | 21.6 (16.3–26.9) | 3,999 | 13.8 (12.4–15.2) | 0.002 |
| Preventive services | | | | | |
| Blood pressure checked in last 2 years | 272 | 96.9 (94.3–99.4) | 3,999 | 97.6 (97.0–98.2) | 0.52 |
| Cholesterol checked in last 2 years | 272 | 88.2 (83.6–92.7) | 3,999 | 86.0 (84.6–87.4) | 0.38 |
| Influenza vaccination in the last year | 272 | 45.1 (37.8–52.3) | 3,999 | 49.2 (47.1–51.3) | 0.27 |
| Cancer screening (among age- and gender-eligible individuals without the specific cancer) | | | | | |
| Breast cancer screening (mammogram within 2 years) among women aged > 40 years | 116 | 63.2 (52.2–74.3) | 1,512 | 75.9 (73.0–78.9) | 0.02 |
| Cervical cancer screening (Pap test within 3 years) among women aged 21–65 years who have not had cervix removed | 91 | 88.9 (81.9–95.9) | 1,386 | 89.8 (87.6–92.0) | 0.80 |
| Colorectal cancer screening (FOBT within 1 year, sigmoidoscopy within 5 years, or colonoscopy within 10 years) among adults aged 50–75 years | 169 | 51.1 (42.0–60.1) | 2,306 | 56.1 (53.4–58.9) | 0.28 |

Note: Boldface indicates statistical significance ($p < 0.05$).

^aHigh OOP burden was defined as having annual out-of-pocket expenditures on health care services in excess of 20% of annual family income.

^bPredicted marginals from a logistic regression model controlling for age, sex, race/ethnicity, marital status, education, and number of comorbidities.

FOBT, fecal occult blood test; OOP, out-of-pocket.